期刊文献+

介入治疗肾上腺原发恶性肿瘤的价值

Value of Interventional Therapy in Primary Adrenal Maiienant Carcinoma
下载PDF
导出
摘要 目的:探讨介入治疗肾上腺原发恶性肿瘤的价值。方法:搜集2001年10月至2002年12月共6例肾上腺原发恶性肿瘤病例经肾上腺肿瘤动脉栓塞介入治疗后分析。结果:6例患者临床表现均明显好转,术后肿瘤明显缩小,其中5例行外科Ⅱ期手术切除或射频消融治疗,1例术后出现转移。结论:介入治疗晚期肾上腺原发恶性肿瘤可为患者创造外科手术治疗或射频消融机会,明显提高生活质量,延长生存期。 Objective To evaluate the value of interventional therapy in phmary adrenal malignant carcinoma. Methods 6 cases of primary adrenal malignant carcinoma treated by interventional therapy from october 2001 to December 2002 were analyzed. Results Improvement of symptoms and decrease of adrenal carcinoma occurred in 6 cases. 5 cases of them could be created by surgical treatment of radiofrequeney ahlation(RFA), 1 case had metastasis aner interv entional therapy. Conclusion Interventional therapy of phmary adrenal malignant carcinoma makes it possible to operate or be created by RFA, to improve qumity of life and extent their lives in patients.
出处 《实用医技杂志》 2006年第3期407-408,共2页 Journal of Practical Medical Techniques
关键词 肾上腺恶性肿瘤 原发 介入性 Adrenal malignant carcinoma Pnmary Interventional
  • 相关文献

参考文献3

二级参考文献19

  • 1Salmenkivi K,Haglund C,Ristimaki A,et al.Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.J Clin Endocrinol Metab,2001,86(11),5615~5619
  • 2Quiros RM,Kim AW,Maxhimer J,et al.Differential heparanase-1 expression in malignant and benign pheochromocytomas.J Surg Res,2002, 108(1),44~50
  • 3Salmenkivi K,Arola J,Voutilainen R,et al.Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis.J Clin Endocrinol Metab,2001,86(5),2231~2235
  • 4Liu J,Voutilainen R,Kahri AI,et al.Expression patterns of the c-myc gene in adrenocortical tumors and pheochromocytomas.J Endocrinol,1997,152(2),175~181
  • 5Gimenez-Roqueplo AP,Favier J,Rustin P,et al.Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.Cancer Res,2003,63(17),5615~5621
  • 6Shimizu K,Namimatsu S,Kitagawa W,et al.Immunohistochemical,biochemical and immunoelectron microscopic analysis of antigenic proteins on neuroendocrine cell tumors using monoclonal antibody HISL-19.J Nippon Med Sch,2002,69(4),365~372
  • 7Yon L,Guillemot J,Montero-Hadjadje M,et al.Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors.J Clin Endocrinol Metab,2003,88(6),2579~2585
  • 8Nakada T,Kubota Y,Sasagawa I,et al.Remarkably suppressed manganese superoxide dismutase activity in malignant pheochromocytoma.J Urol,1995,153(6),1787~1790
  • 9Linnoila RI,Keiser HR,Steinberg SM,et al.Histopathology of benign versus malignant sympathoadrenal paragangliomas:clinicopathologic study of 120 cases including unusual histologic features.Hum Pathol,1990,21(11),1168~1180
  • 10Salmenkivi K,Haglund C,Arola J,et al.Increased expression of tenascin in pheochromocytomas correlates with malignancy.Am J Surg Pathol.2001,25(11),1419~1423

共引文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部